NCT03971929View on ClinicalTrials.gov

Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

September 3, 2020

Study Completion Date

September 3, 2020

Conditions
Hypertension
Interventions
DRUG

SHR0532

once daily(QD) for 4weeks

DRUG

SHR placebo

once daily(QD) for 4weeks

DRUG

Hydrochlorothiazide 25 mg

once daily(QD) for 4weeks

Trial Locations (1)

310009

The second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03971929 - Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension | Biotech Hunter | Biotech Hunter